New cancer treatments developed here at Nationwide Children’s Hospital can more quickly be shared with hospitals across the country and around the world. This means children everywhere will now have faster access to our discoveries and the most advanced cancer treatment possible.
The NEXT Consortium is a collaborative research model that unites multiple research centers with the goal of expediting the most advanced treatments in the shortest time frame possible in pediatric oncology, hematology and bone marrow transplant. Through this nation-wide effort, the goal is to contribute to the development of promising new therapies in pediatric disorders such as childhood cancer, blood disorders, stem cell therapies and other cellular therapies.
By involving many academic institutions, the consortium allows enhanced scientific collaboration between professionals while expanding clinical research resources such as Clinical Scientific Review and Central IRB models. The consortium will strive to streamline the processes for clinical trial operational support, while also providing funding and budgeting support.
Through this collaborative approach, the NEXT Consortium aims to:
Develop investigator initiated innovative research studies that exchange best practices in research and utilize the shared resources from the NEXT Consortium staff.
Maintain a research model that streamlines the clinical trial infrastructure without duplication of efforts from participating institutions. These efforts are inclusive but not limited to: Central IRB, data capture and reporting, expedited subject recruitment, enrollment tracking, data safety monitoring and fiscal management.
Efficiency and dedication to current Good Clinical Practice is coordinated through the mechanisms of this centralized research model.
For more information about the NEXT Consortium, please email Myeshia Harmon.
Head Start 4
One of the first research initiatives to operate within the NEXT Consortium will be the “Head Start 4” protocol. Head Start 4 is a tailored radiotherapy-avoiding approach to the treatment of newly diagnosed malignant central nervous system tumors of young children. For many children, the treatment of this type of cancer can have long-term negative impacts on their development and overall health. The goal of this particular initiative is to use a brief but intensive course of chemotherapy for these young children to both improve the cure rate and the quality of survival through minimizing long-term side effects. Jonathan L. Finlay, MB, ChB, FRCP, Director of Neuro-Oncology at Nationwide Children’s is the principal investigator of the Head Start series. This will be the fourth sequential Head Start study conducted by Dr. Finlay during the past 25 years.
Request Access to The NEXT Consortium
Click the button below to complete an online form to request access to The NEXT Consortium. As part of your submission, you may need to include supporting documents:
- Accessing SharePoint Website (Only): In order for any external user to obtain access to our secure NEXT Consortium Website they will need to submit their acknowledgement of ISSEC.6.0 Confidentiality and Technology Use Agreement. Click here to download the document.
- Accessing Redcap and SharePoint Website: In order for any external user to obtain access RedCap they will need to complete the Redcap External User Agreement and submit their acknowledgement of ISSEC.6.0 Confidentiality and Technology Use Agreement. Click here to download the document.